Skip to main content
S&P 5007,729.77-0.18%DOW52,372.74-0.20%NASDAQ26,273.60-1.04%BTC$81,514.00+1.23%ETH$2,357.82+1.14%GOLD$4,032.00-0.48%OIL$100.19-2.52%
Smart Investors Daily
SID Premium
GH

NASDAQ · GHRS

GH Research PLC

Healthcare · Biotechnology

$20.71

Up+$1.08 (+5.21%)

Updated Oct 29, 2026, 2:34 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
857.25M
P/E ratio
-20.9
Dividend yield
0.00%
52-week range
$12.77 – $31.44
Volume
198.76K
Avg. volume
321.53K

Price performance · GHRS

GHRS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 28, 2026

GHRS closed at $20.71 after 21 trading sessions, down 11.80% for the selected period.

Last close
$20.71
Period change
-11.80%
Period low
$18.07
Period high
$23.48
Daily close
View OHLC price history
GHRS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 28, 2026$19.91$20.79$19.52$20.71198.76K
Oct 27, 2026$19.18$20.22$18.745$20.02299.98K
Oct 26, 2026$18.16$19.31$18.065$19.18306.08K
Oct 23, 2026$18.46$18.59$17.54$18.07699.43K
Oct 22, 2026$18.83$19.00$18.425$18.50329.18K
Oct 21, 2026$19.22$19.81$18.805$18.91393.9K
Oct 20, 2026$18.30$19.43$18.11$19.165277.23K
Oct 19, 2026$18.22$19.07$18.02$18.28323.29K
Oct 16, 2026$18.92$19.3215$18.05$18.15162.61K
Oct 15, 2026$18.75$19.39$18.48$18.81276.72K
Oct 14, 2026$18.64$19.19$18.29$18.56304.39K
Oct 13, 2026$19.88$19.90$18.72$18.85426.56K
Oct 12, 2026$21.05$21.23$20.01$20.02229.89K
Oct 9, 2026$20.66$21.30$20.45$21.11146.04K
Oct 8, 2026$20.94$21.065$19.87$20.45334.27K
Oct 7, 2026$21.39$22.17$21.00$21.06304.77K
Oct 6, 2026$22.23$22.27$21.21$21.52495.43K
Oct 5, 2026$23.00$23.00$21.862$22.17206.96K
Oct 2, 2026$23.05$23.12$22.36$22.94230.11K
Oct 1, 2026$23.31$23.90$22.53$22.86255.12K
Sep 30, 2026$24.92$24.92$23.13$23.48384.73K

Latest GHRS news

The latest Smart Investors Daily articles mentioning GHRS.

Stock researchCompany · Overview

GHRS research

Overview

Company profile and research snapshot.

Company profile

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$27.00
Implied upside
—
Analysts
—
GHRS recent ratings
DateFirmRatingTarget
Aug 7, 2026GuggenheimBuy—
Aug 7, 2026Cantor FitzgeraldOverweight—
Aug 6, 2026NeedhamBuy—
Jul 27, 2026Wells FargoOverweight—
May 19, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 18, 2026

GH Research (GHRS) Stock May Look Stretched As Book Value Trails Price

GH Research has delivered a powerful share price run over the past few years, yet the recent pullback puts fresh attention on a basic question. Is the current US$18.15 price still in line with what its balance sheet and book value can support? Over the past 3 years, GH Research has returned about 149.3%, which puts a lot of weight on whether the underlying net assets can justify that kind of step up. The business model leans heavily on research progress and funding flexibility, so balance...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By